SCHEMBL4689147

SCHEMBL4689147

CCOC(=O)c1cn2c(c1O)C(=O)N(Cc1cccc(Cl)c1)CC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
P2RX7 Q99572 1/20 0.44
MAPK3 P27361 2/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 3/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TP53 P04637 1/20 0.41
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14107111 0.90 P2RX7 (0.46) KMT2ASMN1; SMN2ALDH1A1KDM4EP2RX7
SCHEMBL4690789 0.90 CRHBP (0.49) KMT2AALDH1A1KDM4EPDE3BPDE3A
SCHEMBL4692958 0.89 MEN1 (0.47) KMT2AALDH1A1KDM4EPDE3BPDE3A
SCHEMBL4691908 0.88 PDE3B (0.46) KMT2ASMN1; SMN2ALDH1A1PDE3BPDE3A
SCHEMBL4688507 0.87 SMN1; SMN2 (0.45) KMT2ASMN1; SMN2ALDH1A1KDM4EMAPK1
SCHEMBL4688442 0.87 ALDH1A1 (0.41) KMT2ASMN1; SMN2ALDH1A1KDM4EPDE3B
SCHEMBL6409444 0.86 P2RX7 (0.49) KMT2AALDH1A1P2RX7MAPK3MAPK1
SCHEMBL4688394 0.85 ALDH1A1 (0.45) KMT2AALDH1A1KDM4EPDE3BPDE3A
SCHEMBL4319220 0.84 PKM (0.43) KMT2ASMN1; SMN2ALDH1A1KDM4EP2RX7
SCHEMBL3987831 0.84 MEN1 (0.44) KMT2ASMN1; SMN2ALDH1A1KDM4EPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539714-B1 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2008-08-13 EP disclosed
US-7399763-B2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-07-15 US disclosed
US-7399763-B2 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-07-15 US disclosed
US-20050288293-A1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288293-A1 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors TYMP, TOP1, REV1 KMT2A 2241/4885SMN1; SMN2 3933/4885ALDH1A1 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.